The biotech sector, as measured by the XBI ETF, fell 3.10% in pre-market trading amid a broader market downturn and negative sector-specific news. The decline was significantly influenced by the FDA's rejection of Summit Therapeutics' lung cancer drug, ivonescimab, causing its stock to drop sharply. [14, 18] This news weighed on the entire biotech industry. The sell-off was compounded by a general risk-off sentiment in the market, with tech and AI-related stocks leading the decline in U.S. stock futures. [1, 3, 4, 5]